The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Encapsidation of Heterologous Entities into Virus-like Particles


Stanford Reference:

08-365


Abstract


Stanford investigators have developed a method to package exogenous entities, inside virus-like particles (VLPs) during cell-free protein synthesis. A variety of cargo, such as sRNAi, toxic material, small proteins, probes, or markers, can be encapsulated by the particle. This technology has a variety of applications, including vaccination, drug delivery, gene delivery, cancer treatment, and diagnostic imaging.

Applications


  • Drug delivery - by encapsidating pharmaceutically active molecules
  • Increase vaccine efficacy - by including encapsidated immune stimulating entities with vaccines
  • Diagnostic imaging - by encapsidating imaging enhancing agents
  • Gene delivery - by encapsidating nucleic acids

Advantages


  • Direct access - any portion of the transcription/translation/VLP assembly environment can be optimized in the cell free environment
  • Fewer steps - cargo is encapsidated at the time of VLP synthesis
  • Cargo control - direct control over the concentration cargo molecules added to the process
  • Less contamination - the environment is more dilute than that of a cell and no endogenous RNA, which might contribute to impurities, is transcribed

Publications



Stage of Research


The investigators have demonstrated use of this method to encapsidate a fluorophore. Additionally, they have successfully used cell-free synthesis to encapsidate a firefly luciferase shRNA into VLPs.

Innovators & Portfolio



Patent Status



Date Released

 3/2/2016
 

Licensing Contact


Irit Gal, Senior Licensing Associate
650-723-1586 (Business)
Login to Request Information

[-] Map/Timeline

92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

more technologies

Related Keywords


therapeutic: vaccine   cancer vaccine   gene delivery   therapeutic: anticancer   therapeutic: antiviral   therapeutic: drug delivery   therapeutic: imaging   therapeutic: immunotherapy   therapeutic: pathogen   therapeutic: peptides   therapeutic: proteins   therapeutic: RNAi   therapeutic: small molecule   therapeutic: viral   Virus-like particles (VLPs)   research tool: protein synthesis   cell-free protein synthesis   
 

   

  

Also of Interest...
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-077 A Novel Protein and Gene Expressed by Human T Cells and Monocytes: Alloreaction-Associated Antigen (ARAg)

Recently Viewed...
S08-365 Encapsidation of Heterologous Entities into Virus-like Particles